Pulmonary Arterial Hypertension (PAH) – Press Release

Pulmonary Arterial Hypertension (PAH) – Market Outlook, Epidemiology, Market Forecast And Competitive Landscape Report – 2020 To 2030, provides the detailed therapy area landscape comprised of disease overview, pathogenesis, biomarker specific patient population, country/region-specific current treatment practice, and market landscape. Epidemiology and segmentation based on classification of PAH. Market forecasting comprises all the current and emerging therapies and the competitive landscape of all emerging therapies.

Market Forecasting:

According to Thelansis, the 8Mm Pulmonary Arterial Hypertension market was estimated at ~$5,365 MN in 2020 and expected to reach ~$ 7,829 MN by the end of 2030 (10 years of markets forecasting), with a CAGR of 3.9%.

Epidemiology and patient segmentation:

According to Thelansis, the total prevalent population of Pulmonary Arterial Hypertension (PAH) in the USA ranges from 54,384 in 2020 to 66,150 in 2030. The overall diagnosed population of PAH in 8MM is expected to increase at a CAGR of 1.73% for the study period, i.e., 2020 – 2030. Diagnosed incidence trends are relatively high in the USA, EU5, and Japan, attributed to the early screening programs and the diagnosis of patients in the early stages of the disease.

According to a literature review in the United States, Pulmonary Arterial Hypertension associated with Connective Tissue Disease is the most common. It accounts for approximately 38% of patients with Pulmonary Arterial Hypertension. The most commonly reported subtype of PAH in adult patients is IPAH, followed by PAH associated with concomitant diseases such as CTD CHD. Depending on the registry, the proportions range from 35% to 63% for IPAH, 10% to 30% for CTD-PAH, 10% to 20% for CHD-PAH, and 5% to 10% for aortopulmonary hypertension-PAH.

Competitive landscape: there are five PAH drugs in late-stage clinical development (Phase IIb or later) and 27 more in early stages (Phase I and Phase II).

Current therapies: Janssen (acquired portfolio from Actelion) dominated the therapeutic landscape for approved therapies. Their PAH portfolio includes ERAs (macitentan, bosentan) PCs (selexipag, Iloprost, epoprostenol); while bosentan is now generic, Actelion has mainly been successful in transitioning the patients from bosentan to macitentan (Opsumit). Macitentan is now eyeing a line extension in CTEPH.

Other players are Bayer and United Therapeutics, which have brands like Adempas (riociguat) and treprostinil portfolio, respectively, Generic PDE5i including sildenafil and tadalafil, also prescribed to PAH patients predominantly in the eastern hemisphere of the word vs. the west.

PAH market is now moving more and more towards upfront dual and triple combinations, which combine several mechanisms like ambrisentan + tadalafil from GSK, which combines ERA and PDE5i mechanisms.

Emerging therapies: The therapies majorly fall under three categories of mechanisms which are Endothelin Receptor Antagonists (ERAs), Prostacyclin Analogs (PCs), and Nitrous Oxide Stimulants (NO). The NO pathway further includes medications working on inhibiting PDE5 or soluble guanylate cyclase (sGC) stimulators.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the treatment.

About Thelansis:

Thelansis specializes in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area, including rare / ultra-rare and mainstream indication. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.